Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data
1 Vaccines Market Access and Outcomes Research Specialty Care Business Unit, Pfizer Inc, 500 Arcola Road, Dock D, COL-D4555, Collegeville, PA 19426-3930, USA
2 OptumInsight, 10 Cabot Road, Suite 304, Medford, MA, 02155, USA
3 Hubert Department of Global Health, Rollins School of Public Health, Emory University, 1518 Clifton Road, N.E – CNR Building Room 6009, Atlanta, GA, 30322, USA
4 Boston University School of Medicine, 670 Albany Street, Boston, MA, 02118, USA
5 Department of Health Policy and Management, Harvard School of Public Health, Harvard University, 718 Huntington Avenue, Boston, MA, 02115, USA
BMC Infectious Diseases 2012, 12:175 doi:10.1186/1471-2334-12-175Published: 3 August 2012
Analysis of US claims data from April 2010 to June 2011 estimated that 39% of the 13-valent pneumococcal conjugate vaccine (PCV13) catch-up eligible cohort would ever receive the catch-up vaccination; a previous analysis assumed 87%.
This updated figure was applied to a previously published 10-year Markov model while holding all other inputs constant.
Our model estimated that the catch-up program as currently implemented is estimated to prevent an additional 1.7 million cases of disease in children aged ≤59 months over a 10-year period, compared with routine PCV13 vaccination with no catch-up program.
Because 39% catch-up uptake is less than the level of completion of the 4-dose primary PCV13 series, vaccine-preventable cases of pneumococcal disease and related deaths could be decreased further with additional uptake of catch-up vaccination in the catch-up eligible cohort.